# 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/1194mo-canakinumab-can-docetaxel-dtx-for-the-second-or-third-line-2-3l-treatment/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Luis Paz‐Ares,Yasuhiro Gotô,W.D.T. Lim,Balázs Halmos,Byoung Chul Cho,Manuel Cobo,J.L. González-Larriba,C. Zhou,Ingel Demedts,Akin Atmaca,Sofia Baka,Bijoyesh Mookerjee,Socorro Portella,Zewen Zhu,Bharani Dharan,Martin Reck |
| Citations | 27 |
| DOI | 10.1016/j.annonc.2021.08.1799 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.annalsofoncology.org/article/S0923-7534(21)04029-1/pdf |
| OpenAlex ID | https://openalex.org/W3204045039 |
| Type | article |
| Year | 2021 |

## Paper authors

- [C. Zhou](https://scholariq.org/researchers/c-zhou/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.